menu
    • menu
    [{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F FAPI-74","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofie Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sofie Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"68-Ga FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofie Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sofie Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"68-Ga FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofie Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sofie Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Sofie Biosciences

    Menu

    Sofie Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sofie Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Sofie Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F FAPI-74

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

                            Details : 18-F FAPI-74 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastrointestinal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : 18-F FAPI-74

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sofie Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Sofie Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga FAPI-46

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

                            Details : 68-Ga FAPI-46 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 02, 2022

                            Lead Product(s) : 68-Ga FAPI-46

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sofie Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Sofie Biosciences

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga FAPI-46

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging

                            Details : [68Ga]FAPI-46 is the Gallium-68 radiolabeled PET tracer consisting of FAPI -46 precursor small molecule critical drug intermediate consisting of a FAPI moiety conjugated with a DOTA chelator.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 12, 2021

                            Lead Product(s) : 68-Ga FAPI-46

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth